We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00338260
Recruitment Status : Completed
First Posted : June 20, 2006
Last Update Posted : February 15, 2022
Information provided by (Responsible Party):
Organon and Co

Brief Summary:
The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.

Condition or disease Intervention/treatment Phase
Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) Drug: MK0954, /Duration of Treatment : 5 Years Drug: Comparator : atenolol /Duration of Treatment : 5 Years Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 496 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy
Study Start Date : June 1995
Actual Primary Completion Date : September 2001
Actual Study Completion Date : November 2001

Resource links provided by the National Library of Medicine

Drug Information available for: Atenolol

Primary Outcome Measures :
  1. Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack)

Secondary Outcome Measures :
  1. cardiovascular death, stroke, myocardial infarction, all-cause mortality, hospitalization for heart failure, new-onset diabetes mellitus

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 55 to 80 years
  • Males and females
  • Hypertension (160-200/95-115 mm Hg
  • ECG evidence of left ventricular hypertrophy

Exclusion Criteria:

  • Need for treatment with angiotensin converting enzyme inhibitors, or open- label angiotensin receptor blockers or beta-blockers
  • Myocardial infarction or stroke within 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00338260

Sponsors and Collaborators
Organon and Co
Layout table for investigator information
Study Director: Medical Monitor Merck Sharp & Dohme LLC

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Organon and Co
ClinicalTrials.gov Identifier: NCT00338260    
Other Study ID Numbers: 0954-133
First Posted: June 20, 2006    Key Record Dates
Last Update Posted: February 15, 2022
Last Verified: February 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertrophy, Left Ventricular
Vascular Diseases
Cardiovascular Diseases
Pathological Conditions, Anatomical
Heart Diseases
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Antihypertensive Agents
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists